ReviewAntiviral research2006
Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus.
Review in Antiviral research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 70 citations in OpenAlex.
- Unravelling Electronic Structure and Molecular Vibrations of Proteins in Virus Using Novel Correlated Plasmon-Enhanced Raman Spectroscopy With Machine Learning.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- SNX10 enhances HCoV-OC43 infection by facilitating viral entry and inhibiting virus-triggered autophagy.Virologica Sinica · 2025Article
- Effects ofiMetaOmics · 2025Article
- Crowdsourcing temporal transcriptomic coronavirus host infection data: Resources, guide, and novel insights.Biology methods & protocols · 2023Article
- Nitric oxide boosters as defensive agents against COVID-19 infection: an opinion.Journal of biomolecular structure & dynamics · 2022Article
- Identification and epitope mapping of swine acute diarrhea syndrome coronavirus accessory protein NS7a via monoclonal antibodies.Virus research · 2022Article
- The Endolysosomal System: The Acid Test for SARS-CoV-2.International journal of molecular sciences · 2022Review
- Structural biology of SARS-CoV-2: open the door for novel therapies.Signal transduction and targeted therapy · 2022Review
- Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV.EXCLI journal · 2022Review
- Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins.Frontiers in immunology · 2022Article
- ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress.Developmental cell · 2021Article
- l-Arginine and COVID-19: An Update.Nutrients · 2021Review
- SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity.Viruses · 2021Article
- Review
- Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.Journal of virology · 2021Article
- ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation.Developmental cell · 2021Article
- Possible Therapeutic Intervention Strategies for COVID-19 by Manipulating the Cellular Proteostasis Network.Advances in experimental medicine and biology · 2021Article
- Pathophysiological mechanisms of liver injury in COVID-19.Liver international : official journal of the International Association for the Study of the Liver · 2021Review
- The percentages of SARS-CoV-2 protein similarity and identity with SARS-CoV and BatCoV RaTG13 proteins can be used as indicators of virus origin.Journal of proteins and proteomics · 2021Article
- Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel coronavirus, termed the severe acute respiratory syndrome coronavirus (SARS-CoV), infected humans in Guangdong, China, in November 2002 and the subsequent efficient human-to-human transmissions of this virus caused profound disturbances in over 30 countries worldwide in 2003. Eventually, this epidemic was controlled by isolation and there has been no human infection reported since January 2004. However, research on different aspects of the SARS-CoV is not waning, as it is not known if this virus will re-emerge, especially since its origins and potential reservoir(s) are unresolved. The SARS-CoV genome is nearly 30 kb in length and contains 14 potential open reading frames (ORFs). Some of these ORFs encode for genes that are homologous to proteins found in all known coronaviruses, namely the replicase genes (ORFs 1a and 1b) and the four structural proteins: nucleocapsid, spike, membrane and envelope, and these proteins are expected to be essential for the replication of the virus. The remaining eight ORFs encodes for accessory proteins, varying in length from 39 to 274 amino acids, which are unique to SARS-CoV. This review will summarize the expeditious research on these accessory viral proteins in three major areas: (i) the detection of antibodies against accessory proteins in the serum of infected patients, (ii) the expression, processing and cellular localization of the accessory proteins, and (iii) the effects of the accessory proteins on cellular functions. These in-depth molecular and biochemical characterizations of the SARS-CoV accessory proteins, which have no homologues in other coronaviruses, may offer clues as to why the SARS-CoV causes such a severe and rapid attack in humans, while other coronaviruses that infect humans seem to be more forgiving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.